Bolt Biotherapeutics’ (BOLT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q3 2025 earnings at ($0.33) EPS.

Separately, Stifel Nicolaus decreased their target price on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, Bolt Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Trading Down 0.1 %

Shares of Bolt Biotherapeutics stock opened at $0.44 on Tuesday. Bolt Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.56. The firm’s 50 day simple moving average is $0.47 and its two-hundred day simple moving average is $0.55. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.79 million. Analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in Bolt Biotherapeutics during the fourth quarter valued at approximately $25,000. Squarepoint Ops LLC acquired a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $26,000. Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $27,000. Citadel Advisors LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at $42,000. Finally, FMR LLC lifted its stake in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.